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ABSTRACT
This report describes an integrated study on identi-
fication of potential markers for gastric cancer
in patients’ cancer tissues and sera based on:
(i) genome-scale transcriptomic analyses of
80 paired gastric cancer/reference tissues and
(ii) computational prediction of blood-secretory
proteins supported by experimental validation.
Our findings show that: (i) 715 and 150 genes
exhibit significantly differential expressions in all
cancers and early-stage cancers versus reference
tissues, respectively; and a substantial percentage
of the alteration is found to be influenced by
age and/or by gender; (ii) 21 co-expressed gene
clusters have been identified, some of which are
specific to certain subtypes or stages of the
cancer; (iii) the top-ranked gene signatures give
better than 94% classification accuracy between
cancer and the reference tissues, some of which
are gender-specific; and (iv) 136 of the differentially
expressed genes were predicted to have their
proteins secreted into blood, 81 of which were
detected experimentally in the sera of 13 validation
samples and 29 found to have differential abun-
dances in the sera of cancer patients versus
controls. Overall, the novel information obtained in
this study has led to identification of promising diag-
nostic markers for gastric cancer and can benefit
further analyses of the key (early) abnormalities
during its development.
INTRODUCTION
Gastric cancer represents the second leading cause of
cancer death worldwide, next only to lung cancer (1).
In 2002, 934000 new cases were reported worldwide.
In the USA,  21500 new cases of gastric cancer were
diagnosed in 2008, with 10800 deaths from the disease
(2). The current 5-year survival rate of individuals
diagnosed with gastric cancer is  24% (1), reﬂecting
the reality that most cases are already in an advanced
stage when diagnosed. As with other cancers, the chal-
lenge in early detection lies in the reality that the early
symptoms tend to be relatively non-speciﬁc, and detection
requires that invasive physical procedures, such as gastro-
intestinal endoscopy, be carried out on a regular basis,
which may not be practical for general screening. The
most ideal solution for early detection is to ﬁnd reliable
markers that can detect the cancer through simple blood
tests.
Recent comparative transcriptomic studies have
identiﬁed a number of gene markers of different types for
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and INHBA (4)], prognostic markers [CDH17 (5), PDCD6
(6)], and gastric-cancer-associated genes [TSPAN1, Ki67
and CD34 (7)]. While exhibiting some predictive
power, these gene markers were found highly incon-
sistent as identiﬁed by different studies (Supplementary
Table S1), and none of them has reached the clinical
trial stage. A few serum markers such as a-fetoprotein
antigen (AFP), carcinoembryonic antigen (CEA), and
CA19-9, identiﬁed through large-scale blood screening
(8), have been used for gastric cancer detection. The detec-
tion sensitivities of these markers are, however, rather low,
no more than 25% at the 90% speciﬁcity level (8), and
hence they have not been widely used clinically for diag-
nostic purposes. Using immunoassay and proteomic
techniques, a few new serum markers were recently
proposed. including MUC1 andMUC5AC (8), pepsinogen
C and pepsin A activation peptide (9), and Reprimo (10),
although their true diagnostic power for gastric cancer,
especially at an early stage, is yet to be thoroughly
evaluated. More rigorous studies are in order on these
proposed markers.
The lack of reliable serum markers for gastric cancer
reﬂects the challenging nature of the problem, but also
suggests the possibility that all the information derivable
using the powerful omic techniques, in conjunction
with computational approaches, may not have been
fully utilized. For example, there have been only a few
published large-scale studies attempting to link the
information derivable from gene-expression proﬁles of
cancer tissues to proteomic biomarker identiﬁcation
in patients’ sera. The general issue with the existing
proteomic studies on serum marker identiﬁcation is
that the potential markers are probably of substan-
tially lower abundance in comparison with other
proteins in blood circulation, making their detection
through large-scale screening extremely difﬁcult. Our
study indicates that transcriptomic analyses of cancer
tissues can provide highly useful information in
guiding proteomic studies in a search for protein
markers in sera.
Herein a systematic study, aiming to ultimately identify
serum markers for gastric cancer, is presented, where the
following procedure was employed. Exon array chips were
made on 80 pairs of gastric cancer and the adjacent
noncancerous tissues from the same patients.
Comparative analyses of gene expression data were per-
formed to identify differentially expressed genes in cancer
versus reference tissues. These genes were then subject to
computational analyses to determine if their proteins may
be secretory into blood circulation and thus potentially
serve as serum markers. To rule out markers that are
non-speciﬁc to gastric cancer, the predicted marker genes
were compared with published microarray
gene-expression data for other human diseases, including
over 40 types of cancers. Then immunoassay and mass
spectrometry (MS) analyses of serum samples from a
subset of the 80 patients and healthy age- and
gender-matched volunteers were used to verify the pre-
dicted markers.
MATERIALS AND METHODS
Sample collection
A total of 80 gastric cancer tissues and their adjacent
noncancerous tissues were collected from 80 non-treated
patients (4 of stage I, 7 of stage II, 54 of stage III and 15 of
stage IV). To ensure the integrity of the mRNAs
used for microarray experiments, all tissues were snap-
frozen and stored in liquid nitrogen within 20min
after resection. In addition, blood samples were col-
lected from the cancer patients before surgery, and
control blood samples were collected from healthy
age-/gender-matched volunteers involved in this study.
All samples were collected at three afﬁliated hospitals
of Jilin University College of Medicine and Jilin
Provincial Cancer Hospital, Changchun, China. A
written informed consent was obtained from all patients,
which was approved by the Institutional Review Board
(IRB) at the University of Georgia, Athens, GA, USA
and by the Chinese IRB overseeing human subjects
at Jilin University College of Medicine and Jilin
Provincial Cancer Hospital. The histological subtype
and pathologic stage of each tumor were determined
according to the World Health Organization (WHO)
and TNM classiﬁcation system. Detailed patient informa-
tion such as age, gender, and pathologic stage, is listed in
Supplementary Table S2.
RNA preparation and microarray experiments
A total of 15mg RNA was extracted from each tissue
sample using Trizol (Invitrogen) followed by puriﬁcation
using the RNeasy Mini kit (QIAGEN) according to the
manufacturer’s recommendation. Ratios of A260/A280
>1.9 and 28S/18S rRNA of 2 were used to ensure that
the RNA samples were highly puriﬁed and not degraded.
The RNA samples were analyzed using the GeneChip
Human Exon 1.0 ST (Affymetrix), following the protocol
detailed in the Genechip Expression Analysis Technical
Manual (P/N 900223). In brief, 1mg of total RNA
was used as template for synthesis of cDNA after
rRNA reduction. Through reverse transcription in vitro,
cRNA was obtained and used as the template for cDNA
synthesis in the second cycle. Then cRNA was hydrolyzed
by RNase H, and the sense strand DNA was digested by
two endonucleases. Fragmented samples were labeled with
DNA labeling reagent. The labeled samples were mixed
with hybridization cocktail and hybridized to the micro-
array at 45 C, 60rpm, and then incubated for 17 h. Next,
the array was washed and stained on the GeneChip
Fluidics Station 450, using the appropriate ﬂuidics
script, before being inserted into the Affymetrix
autoloader carousel and scanned using the GeneChip
Scanner 3000 with GeneChip Operating Software
(GCOS).
The raw exon array data (.CEL) collected on the 80
pairs of cancer and reference tissues is MIAME compliant
and can be temporarily downloaded at http://csbl.bmb
.uga.edu/ juancui/Data/data.tgz.
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We used the expression data of the 290000 core probe sets
supported by the full-length mRNAs from the Refseq
database. The probe intensities were normalized using
the quartile normalization by the MiDAS (Microarray
Detection of Alternative Splicing) program (see
Affymetrix white paper exon_alt_transcript_ analysis_
whitepaper.pdf), and then summarized to both exon-
and gene-level expressions using the PLIER algorithm
(11) (see ‘Guide to Probe Logarithmic Intensity Error
(PLIER) Estimation’ at http://www.affymetrix.com/
support/technical). All genes having very low expressions
were then removed from our analysis since the
signal-to-noise ratio is rather low among such genes; spe-
ciﬁcally, a gene was removed if its normalized average
expression level in both the cancer and the reference
groups was below 10. To detect genes with consistent
differential expressions in cancer versus reference tissues,
an analysis of variance (ANOVA) test and a paired
Wilcoxon signed–rank test were performed, along with a
third statistical test outlined as follows. For each gene, the
number of pairs of cancer/reference tissues, Kexp, whose
expression fold-change is larger than k (k is set to be 2)
was counted; if the P-value for the observed Kexp was
<0.05 (see details in Supplementary Procedure 1), the
gene was considered to have differential expression in
cancer versus reference tissues. All statistics are listed in
Supplementary Table S3.
Bi-clustering analysis and pathway enrichment analysis
Our in-house bi-clustering QUBIC (QUalitative
BI-Clustering) program (12) was used to identify statistic-
ally signiﬁcant bi-clusters in the expression data. The basic
idea of the algorithm is to ﬁnd all subgroups of genes with
similar expression patterns among some (to be identiﬁed)
subsets of cancer tissues, and hence genes involved in each
such pattern can possibly be used as signatures for cancer
sub-typing or staging. Compared to existing algorithms,
QUBIC can solve more general form of the bi-clustering
problem in a computationally efﬁcient manner (12).
The pathway enrichment analysis was ﬁrst done using
two popular programs, DAVID (13) and KOBAS (14).
Additional curated pathway information from Human
Pathway Interaction Database (15) was integrated to
ensure a comprehensive coverage, and a P-value was
calculated for each relevant pathway based on Fisher’s
exact test on queried genes against the whole human
genome.
Identiﬁcation of gene signatures and prediction of
blood-secreted proteins
A signature-selection procedure (see details in
Supplementary Procedure 2) was used to systematically
identify multi-gene combinations whose gene-expression
levels can distinguish well between cancer and reference
tissues. To ensure the robustness of the to-be-identiﬁed
signatures, we randomly and repeatedly sampled the
paired tissues and predicted the possible multi-gene
signatures for each sample set; and then ranked the signa-
tures derived from different sample sets using a consensus
voting procedure (16).
Among the differentially expressed genes, we focused on
those whose proteins are predicted to be secretory to
blood circulation by our in-house program (17). To the
best of our knowledge, this is the ﬁrst program for predic-
tion of blood secreted proteins. The basic idea of the al-
gorithm is as follows. An extensive literature search led to
a large collection of human proteins that are known to be
blood secretory and detected by previous proteomic
studies. A list of features shared by these blood secretory
proteins was delineated, including their physical and
chemical properties, amino acid sequence and motif,
and structural features. Using these features, a support
vector machine (SVM)-based classiﬁer was trained to
distinguish proteins that are blood secretory from those
that are not. The trained classiﬁer achieved  90% predic-
tion sensitivity and 98% speciﬁcity based on a large test
set consisting of 98 known blood-secretory proteins and
6601 non-blood-secretory proteins (17).
Public microarray data for gastric cancer as an
independent validation set
Two public microarray datasets for gastric cancer from the
GEO database were downloaded for comparative studies
(Supplementary Procedure 3). The Kim dataset (18), with
gene expression proﬁles of 50 gastric cancer patients in
different cancer stages, was used to evaluate the effect-
iveness of the predictive markers through examining the
consistency of their expression alteration across all
samples. Given the ratio of the expression levels between
the cancer tissues and the reference tissues, the data was
normalized using the print-tip Lowess method in the
marray package of the Bioconductor project (http://
www.bioconductor.org) (19). The original study showed
that the comparison of the log-transformed fold-changes
between this dataset and the Affymetrix array is meaning-
ful (18). The Xin dataset (20), with gene expression
of 100 gastric cancer and 24 reference tissues, was ﬁrst
preprocessed using essentially the same procedure as
described by Chen et al. (20). This data were used to test
the robustness and effectiveness of the predicted markers
through the same classiﬁcation analysis applied on our
dataset.
Speciﬁcity analysis of predicted gene markers through
searches against public microarray data
To assess the speciﬁcity of the predicted gene markers to
gastric cancer, a biomarker evaluation system (http://
bioinfosrv1.bmb.uga.edu/DMarker/) was developed to
check if the expression pattern of the predicted markers
could also be caused by other human diseases. The basic
idea is to collect all the microarray datasets for human
diseases from the GEO (21), Oncomine (22) and SMD
(23) databases after removing datasets with less than six
samples in either cancer or the reference group, removing
the genes with all their expression levels among the bottom
10% of the expression levels in each dataset, and genes
with more than 50% values being missing within each
Nucleic Acids Research,2011, Vol.39, No. 4 1199dataset and 30% missing across all diseases. A marker is
considered speciﬁc to gastric cancer only if no more than
30% of the patients and the control populations for
any other disease dataset satisfy the expression cutoff for
the marker, where 30% is determined empirically based on
our studies.
Experimental validation of predicted serum markers
A combined approach of MS, antibody array and western
blot analysis was used to validate the predicted serum
markers. Brieﬂy, for western blots, serum samples
were incubated at 100 C for 5min, separated using
SDS–PAGE gels (Bio-Rad), and then transferred
onto PVDF membranes. After blocking the non-speciﬁc
binding sites, membranes were incubated overnight
at 4 C with primary antibodies in 1.5% non-fat dry milk
in TBST, followed by incubation with secondary
antibodies for 2h. The antibodies were from Abnova,
Inc. (Taipei, Taiwan), Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA) and Abcam, Inc. (Cambridge, MA).
The enhanced chemiluminescence (ECL) reaction, using
Western Lightning Chemiluminescence Reagent Plus
(Perkin Elmer, USA), was then applied to the membranes,
and the ECL membrane images were quantiﬁed using the
ImageJ 1.34s software (http://rsb.info.nih.gov/ij/).
MS experiments were conducted on proteins extracted
from gels (SDS–PAGE). The samples were digested with
proteomics-grade Trypsin (Promega) and analyzed on an
Agilent 1100 capillary LC (Palo Alto, CA) interfaced
directly to an LTQ linear ion trap mass spectrometer
(Thermo Electron, San Jose, CA). The peptide samples
were loaded using positive N2 pressure on a PicoFrit
8cm by 50mm column (New Objective, Woburn, MA).
Peptides were eluted from the column into the mass
spectrometer during a 55min linear gradient from 5 to
60% of total solution composed of mobile phase B at a
ﬂow rate of 200nl min
 1. The instrument was set to
acquire MS/MS spectra on the nine most abundant pre-
cursor ions from each MS scan with a repeat count of
three and repeat duration of 15 s. Data analysis was con-
ducted using MASCOT (http://www.matrixscience.com),
searching against the NCBI Human database and a
reverse NCBI Human database. The assigned peptides
were grouped into proteins using the ProteoIQ software
(http://www.bioinquire.com). Only proteins with a false-
discovery rate of <1% were considered statistically
signiﬁcant.
For the biotin-label-based array experiment, each
sample (50ml serum) was dialyzed, followed by a
biotin-labeling step (Pierce, Rockford, IL, USA),
where the primary amine was biotinylated. The
biotin-labeled proteins were incubated with chips
(RayBioBiotin Label-Based Antibody Arrays,
RayBiotech, Inc.) at room temperature for 2h. After
the incubation with HRP-streptavidin, the signals were
visualized by chemiluminescence and then imaged by a
Scan Array laser confocal slide scanner (PerkinElmer
Life Science).
RESULTS
Differentially expressed genes in gastric cancer versus
reference tissues
A total of 80 gastric cancer tissues and their adjacent ref-
erence tissues from the same 80 patients were collected
(Supplementary Table S1). Microarray experiments were
conducted on these tissues using the Affymetrix GeneChip
Human Exon 1.0 ST Array, which covers 17800 human
genes. Using a set of criteria given in ‘Materials and
Methods’ section, 2540 genes were found to exhibit differ-
ential expression patterns between the cancer and the ref-
erence tissues, of which 715 showed at least 2-fold changes
in expression (detailed information of each gene is listed in
Supplementary Table S3). The majority of these genes
were up-regulated in cancer and only one-ﬁfth was
down-regulated (Supplementary Figure S1). In addition,
1276 genes were found to be differentially expressed in
early-stage cancers (stages I–II), with 468 genes speciﬁc
in early stage (i.e. having no substantial differences in
the advanced cancers). Of the 1276 genes, 208 were con-
sistently differentially expressed across all early-stage
paired samples, 48 of which are gastrointestinal
diseases-related (Supplementary Table S3).
Our observations about the altered gene-expressions in
gastric cancer are largely consistent with the previous
reports (Supplementary Table S1), such as the altered ex-
pression of TOP2A, CDK4 and CKS2 (24), CDH1 (25),
GKN1, GKN2 and TFF1 (26,27). Some novel observa-
tions were also made. For example, a number of genes
related to chromosomal ampliﬁcations, transcriptional
regulation and signal transduction, such as CCNE1,
POP4, RMP, UQCRFS1 and DKFZP762D096, were
found to exhibit differential expressions in 55 of the 80
( 68.7%) cancer samples used in our study. This percent-
age is signiﬁcantly higher than that in a previous report
(20). The observed up-regulation of two claudins, CLDN
7 and CLDN1, and down-regulation of DPT are found in
most cancer tissues, regardless of their stage and subtype,
potentially serving as gene markers for gastric cancer. We
believe that the differences in some of our observations
with the previous one may be due to different distributions
of the patient populations in terms of age, gender and
cancer subtype/stage used in different studies. In
addition, a number of down-regulated genes were found
by this study to be highly speciﬁc to gastric cancer. These
include GIF, GNK1, GNK2, TFF1, GHL1, LIPF and
ATP4A, providing a different type of marker with
decreased abundance in cancer.
Enriched functional families and pathways
According to IPA (Ingenuity Pathway Analysis; http://
www.ingenuity.com) annotation, 911 out of the 2540 dif-
ferentially expressed genes are cancer-related, 219 related
to antigen presence or immune responses, with 414 being
gastric tissue speciﬁc. Among the 13 major IPA functional
families, 9 and 10 families are found to be substantially
enriched (P<0.01) among the 2540 differentially
expressed genes and the 911 cancer-related genes, respect-
ively, when compared with the whole human genome
1200 Nucleic Acids Research, 2011,Vol.39, No. 4(Supplementary Figure S2). Some interesting observations
are made. For example, the level of enrichment in kinases,
peptidases, enzymes, transporters and transmembrane re-
ceptors increases as cancer develops from early to
advanced stages; transcription regulators are enriched
only in early-stage cancers; and growth factors are more
substantially enriched in early cancers than in advanced
cancers. Among the 23 transcription factors that are
consistently up- or down-regulated across at least 80%
of all early-stage cancers in our study, signals possibly
related to the early responses to cancer development
were observed, such as the up-regulation of repressor
E2F4/DP1, which may regulate cell growth and differen-
tiation by the TGF-b signaling pathway, and the
up-regulation of p14ARF, an upstream regulator of the
TP53 pathway that inhibits the apoptosis.
Pathway enrichment analysis was conducted on the
differentially expressed genes. Table 1 lists 13 such
pathways, along with their statistical signiﬁcance values.
A few general cellular processes such as the cell cycle,
DNA replication and cell communication were highly
enriched by consistently up-regulated genes, while fatty
acid metabolism, digestion and ion transport were
enriched only by down-regulated genes. Most of these
pathways start being up- or down-regulated in early-stage
cancers and become increasingly more enriched as cancer
advances. In addition to the pathways commonly
associated with cancer development such as cell cycle
and regulation, DNA damage and repair, cell growth,
apoptosis and regulation, and estrogen receptor regulation
pathways, a few gastric cancer-speciﬁc pathways were
revealed. For example, a novel thyroid hormone-mediated
gastric carcinogenic signaling pathway (28) is enriched
with up-regulated genes (TTHY, PKM2, GRP78,
FUMH, ALDOA and LDHA) in cancer tissues, most of
which are in advanced stages.
Effects of age and gender on gene expression data
The impact of age and gender on the expressions of
the 2540 differentially expressed genes was assessed
through multivariate analyses using ANOVA (11) and
Cox Proportional Hazard Regression Model (29)
(Supplementary Table S4). It was found that age signiﬁ-
cantly affects the expressions of 143 genes (P<0.05),
113 of which further increase the differences in their
expression levels between cancer and reference tissues,
an observation that could have important implications
to biomarker selection. For example, the average MUC1
expression level is substantially higher in cancer tissues of
patients over 55 versus those under 55 (Supplementary
Figure S3). Similar observations were made on a few
other genes such as UBFD1, MDK and the other
members of the Mucin family. The observation that age
might impact on the expression of certain genes might
correlate to some degree with the ﬁnding that poorly
differentiated cancers are more aggressive and more
common in young patients (30–32).
Possible gender-speciﬁc biases in our expression data
were also examined, knowing that the male-to-female
ratio of gastric cancer occurrences is about 2:1 (33). It
was found that the expression levels of 59 genes, including
WNT2, ARSE and KCNN2, are gender-dependent
(Supplementary Table S4). An interesting observation
was that the combination of age and gender has a more
signiﬁcant effect on the expression levels of 118 genes such
as COL1A1, THY1 and CPS1. For genes like TIMP1 and
ADH1A, older male patients have higher expression levels
than younger female patients.
Among the differentially expressed genes speciﬁc to
early-stage cancers, 28 and 9 genes are age- and gender-
dependant, respectively; examples include P2RY6 and
NSUN5. Other factors such as alcohol-/smoking-taking
history were also evaluated using a multivariate analysis,
and the detailed results are given in Supplementary
Table S4.
Co-expressed gene clusters relevant to cancer classiﬁcation
To discover novel associations of gene expression patterns
with speciﬁc subtype and stage of gastric cancer, we have
carried out a bi-clustering analysis of gene-expression data
using an in-house program QUBIC (12). Twenty-one stat-
istically signiﬁcant bi-clusters have been identiﬁed which
are cancer-, stage- or subtype-speciﬁc (Supplementary
Table S5). Figure 1A shows two bi-clusters (C1 and C2)
with the highest statistical signiﬁcance among the 21, each
representing a group of genes with correlated expressions
across a majority of the 80 pairs of samples. Analyses of
these two bi-clusters revealed that: (i) genes such as tran-
scriptional regulators, growth factors and enzymes
involved in cell-cycle regulation (STMN1 and CDCA8),
transcription regulation (TCF19 and BRIP1), angiogen-
esis (IL8), chromosome integrity (TOP2A) and extracellu-
lar matrix remodeling (MMPs) were up-regulated starting
at a very early stage of gastric cancer (in C1), while genes
involved in metabolism are down-regulated (in C2); the
coordinated expression patterns across genes in each of
the two bi-clusters may suggest coordinated regulations
Table 1. Thirteen enriched pathways by differentially expressed genes
Pathways Number of genes P-value
Stages I–II
(speciﬁc)
All
stages
Cell cycle 22" (9")4 9 " 1.59E–21
p53 signaling pathway 10" (3")2 7 " 2.66E–12
ECM-receptor interaction 4" (–) 31" 8.18E–13
Cell communication 6" (–) 34" 4.70E–04
Cell adhesion molecules (CAMs) 4" (2")3 1 " 5.13E–04
Role of BRCA1, BRCA2 and
ATR in cancer susceptibility
4" (–) 10" 2.90E–03
E2F1 destruction pathway 4" (–) 6" 8.00E–03
Wnt signaling pathway 4" (–) 17" 2.22E–02
Focal adhesion 4" (3")4 1 " 1.32E–09
3# (3#)4 # 9.81E–02*
Metabolism of xenobiotics
by cytochrome P450
4# (–) 16# 7.21E–04*
Arginine and proline metabolism 3# (–) 3# 1.16E–03*
Fatty acid metabolism 3# (–) 7# 2.56E–03*
Insulin signaling pathway 5# (–) 7# 9.37E–04*
Upward arrow indicates for up-regulation and downward arrow indi-
cates down-regulation. P-value is calculated for a pathway enriched in
all stages except those marked with asterisks are for early stage only.
Nucleic Acids Research,2011, Vol.39, No. 4 1201across these genes; and (ii) most genes in C1 and C2 show
discerning power between the cancer and the reference
tissues, even at stage I.
Some genes were found to exhibit distinct expression
patterns speciﬁc to different cancer stages. For example,
in Figure 1B, two gene clusters show at least 2-fold
changes in gene expression across the majority of stage
III cancer tissues versus the corresponding references,
but not at other stages. This group of genes can serve as
potential markers for measuring the progression of gastric
cancer.
Another bi-cluster could provide useful information
about subtypes. In this bi-cluster containing 42 genes
(Figure 1C), 6, namely CNN1, MYH11, LMOD1,
A
B
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C
Figure 1. Identiﬁed bi-clusters across 80 samples over subsets of genes, where each row represents a gene and each column represent a pair of cancer/
reference tissues. (A) C1 shows 244 genes that are consistently up-regulated in cancer versus reference tissues; C2 shows 95 genes, most of which are
down-regulated. Note that the order of the tissue samples for different bi-clusters is not necessarily the same since the algorithm rearranges the order
of tissue samples. (B) Two clusters speciﬁc to stage III, consisting of genes with at least 2-fold expression changes across most of stage III patients
but not other stages. (C) A bi-cluster possibly subtype-speciﬁc, consisting of 42 genes. The six genes highlighted within orange bars are known to be
subtype-associated in gastric cancer.
1202 Nucleic Acids Research, 2011,Vol.39, No. 4MAOB, HSPB8 and FHL1, have been previously reported
to be differentially expressed between the intestinal and
the diffuse subtypes of gastric cancer (18). Our analysis
indicates that these 42 genes can better distinguish the two
possible subtypes of gastric cancer (gene names listed in
Supplementary Table S5) although further studies on a
larger dataset are needed to conﬁrm this suggestion. We
noted that none of the 21 co-expression clusters was
gender-speciﬁc.
Gene signatures for gastric cancer
A number of genes were found to have distinguishing
expression patterns between the cancer and the reference
tissues, based on a classiﬁcation analysis using RFE-SVM
(see ‘Materials and Methods’ section). Figure 2A
(red curve) summarizes the classiﬁcation accuracies for
the optimal k-gene combinations (markers) for k from 1
to 100, derived using our gene-signature identiﬁcation
program, where a 28-gene combination gives the best
accuracy, having 95.9 and 97.9% agreement with the
cancer and reference tissues, respectively (Figure 2B).
Our design of the RFE-SVM-based procedure took into
consideration the classiﬁcation accuracy, stability and
reproducibility of the identiﬁed signatures, and hence the
results are highly robust. A drawback of the method is
that it may not necessarily ﬁnd the best k-gene markers
due to its heuristic nature, which allows us to search for
large k-gene combinations efﬁciently. Thus, we have also
carried out an exhaustive search for the best k-gene
Figure 2. (A) The red curve represents the overall classiﬁcation accuracies of k-gene markers (k=1,...,100), which is the average of the best
accuracies of 500 randomly selected subsets; the blue curve represents the best 5-fold cross validation accuracy of k-gene markers (k=1, 2,...,8),
identiﬁed through an exhaustive search. (B) The heatmap for the best 28-gene marker, comprising of 13 up-regulated and 15 down-regulated genes.
Among them, NKAP, TMEM185B, C14orf104 and C1orf96 are up-regulated, while KLF15, PI16 and GADD45B are down-regulated across >89%
early-stage patients.
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for small k values, speciﬁcally for all k 8, which guaran-
tees to ﬁnd the globally optimal combinations, using a
linear SVM approach (34). This method, however, does
not scale up to larger k values due to the intrinsic
complexity of the exhaustive search. The performance
of the identiﬁed k-gene markers was evaluated using
5-fold cross validation. In Figure 2A, the best accuracies
of the so identiﬁed k-gene markers (k=1,...,8) are
consistently better than those by RFE-SVM. These
marker genes are found to be mostly associated with
the regulation of cell growth and apoptosis such as
cell cycle, ECM-receptor interaction, CDK regulation of
DNA replication and the TNFR1 signaling pathway
(Supplementary Table S7).
An interesting and unexpected observation was that
some markers perform very well on some groups of
patients, but not on others. For example, there is a discrep-
ancy between the marker performance for patients of dif-
ferent gender and different ages, which is consistent with
our previous observation that age and gender have consid-
erable effects on expressions of some genes. To overcome
this problem, separate marker searches were conducted
for different genders. The detailed list of the markers so
identiﬁed are given in Supplementary Table S7, including
the top markers LIPG, INHBA and TTYH3 for women
and WNT2, CD276 and MFAP2 for men.
A similar analysis on early-stage cancers was also
carried out, and a number of promising markers speciﬁc
to early-stage gastric cancer were identiﬁed for k 4
(Supplementary Table S7). Overall, we found that the
best single-gene marker, namely HIST1H3F or CCL20,
can have 94.4% classiﬁcation agreement, 100% for
cancer and 88.9% for reference tissues, respectively. This
number improves to 97.3% when using the best four-gene
combination (GAL3ST4-PPA1-HOXA13-HIST1H3F).
To examine the generality of the predicted gene
markers, their classiﬁcation accuracies were checked on
previously published large microarray datasets for
gastric cancer. On the Xin dataset (20), the success rates
of our k-gene markers range from 81.7 to 100% when
k goes from 1 to 7. When evaluated on the early-stage
samples from the Kim dataset (18), our single-gene
markers such as TFF3, CLDN4, MDK and MUC13
have consistent differential expression patterns across
80% (12 of 15) of the early-stage samples. Overall, these
results indicate that our identiﬁed tissue markers are gen-
erally applicable. In addition, the speciﬁcity analysis
enabled us to assess the speciﬁcity of each predicted
marker, through which we obtained a few genes which
are highly speciﬁc to the gastric cancer such as CKB and
ATP4A.
Predicted serum markers for gastric cancer
Out of the 783 genes with at least 2-fold changes in
expression levels across all cancer (or early-stage cancer)
versus their reference tissues, a total of 136 genes were
predicted to be blood-secretory by our program, respect-
ively (17). A number of these proteins could potentially
serve as serum markers for gastric cancer, which are
grouped into three categories: (i) general markers for
gastric cancer, (ii) markers speciﬁc to early-stage cancer
and (iii) gender-speciﬁc markers. Table 2 lists 18 such
proteins that we consider as promising serum markers
for gastric cancer (details in Supplementary Table S8)
based on their fold-change of expression in cancer tissue.
Among them, MMP-1, Mucin-13 and cathepsin-B are ef-
fective gene discriminators between cancer and reference
tissues, but they are not speciﬁc to gastric cancer accord-
ing to our speciﬁcity analysis against public microarray
data and the previous reports of their over-expression in
other cancers such as breast, ovarian, lung and colon
Table 2. Eighteen promising predictive markers for gastric cancer
Serum marker Stage efﬁciency Gender speciﬁcity
General Early Female Male
MMP1 MMP-1, Matrix metalloproteinase 1 preproprotein ˇ
MUC13 Mucin 13 ˇ
CTSB Cathepsin B ˇˇ
GKN2 Gastrokine 2 ˇˇ
GHRL Appetite-regulating hormone (ghrelin) ˇ
LIPF Gastric triacylglycerol lipase (gastric lipase) ˇˇ
LIPG Endothelial lipase ˇˇ
LIMK1 LIM domain kinase 1 ˇ yy
GAST Gastrin ˇ
GIF Gastric intrinsic factor ˇ
AZGP1 Zinc-alpha-2-glycoprotein ˇˇ
CLDN1 Claudin-1 ˇ
MDK Midkine ˇˇ
TOP2A Topo-IIA;DNA topoisomerase 2-alpha ˇˇ
CST1 cystatin SN ˇ
PDGFRB PDGFR-b ˇ
PGA4 Pepsin A ˇˇ
COL10A1 Collagen alpha-1(X) ˇ
Check mark denotes the condition that a gene shows good classiﬁcation performance; dagger indicates that a gene has good classiﬁcation accuracy
but is gender-independent.
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gastric intrinsic factor, ghrelin and gastrokine 2 are,
however, gastric tissue-speciﬁc, thus making them more
promising serum markers for gastric cancer, particularly
when used in conjunction with other markers.
Experimental validation of the predicted markers
Western blot analysis was conducted to validate the
18 aforementioned proteins on serum samples from nine
gastric cancer patients and ﬁve controls. Of the 18, 15 were
successfully detected, among which 5 proteins, Mucin-13,
gastric lipase, Topo IIA, gastrokine 2 and collagen
alpha-1(X), show a detectable level of differential abun-
dance between the sera of the cancer patients and the
control group, with the ﬁrst three showing substantial
differences (Supplementary Figure S4A). This ﬁnding
suggests that our prediction approach is sufﬁciently
sensitive to predict potential serum markers.
The validation of the predicted markers was then
expanded beyond those 18 proteins by conducting a
large-scale screening on the serum samples using MS
analyses and Biotin label-based antibody array experi-
ments (36). Considering the sensitivity limitation of MS,
the sera from the cancer patients and the controls was
pooled, respectively, to enrich the potential markers.
Excluding the native high abundance serum proteins
(Supplementary Table S9), 81 proteins were identiﬁed
with high conﬁdence using MS. The Biotin array has
507 human proteins ﬁxed on the array (details in
Supplementary Table S10). Together, these two comple-
mentary techniques identiﬁed 67 out of the 136 computa-
tionally predicted potential serum markers, of which 24
proteins were found with differential abundance in sera
samples from cancer patients versus the controls
(Supplementary Table S10). The differential expressions
of eight such proteins are shown in Supplementary
Figure S4B, where it can be seen (top panels) that four
proteins, EGFR (ErbB1), GRO (CXCL1), IL-1 alpha
(IL1A) and osteoprotegerin (TNFRSF11B), are more
highly expressed in cancer versus control sera, while the
other four proteins (cf. bottom panels), including sFRP-4
(SFRP4), MMP-3 (MMP3), LIF and PARC (CCL18),
consistently exhibit decreased abundance in the sera of
cancer patients.
Among the other experimentally detected proteins,
cathepsin B shows no signiﬁcant differential abundance
across the cancer versus control samples, a ﬁnding incon-
sistent with previous reports proposing it as a potential
serum marker (37,38). MMP-1 and Topo-IIA have been
previously suggested as cancer related in general (35),
which is supported by our data. GKN2 and LIPF are
gastric tissue-speciﬁc, and collagen alpha-1(X) and
gastrin may be associated with other diseases or an
immune response in general (details in Supplementary
Table S8).
Overall, we have identiﬁed two types of potential serum
markers: (i) proteins with substantially altered abundance
in advanced cancer, including the proteins identiﬁed by
antibody arrays, such as sFRP-4, MMP-3, LIF, PARC,
EGF R, GRO, IL-1 alpha and osteoprotegerin, and three
proteins identiﬁed by western blot, Mucin-13, gastric
lipase and Topo-IIA. Among these potential markers,
Mucin-13 functions in several signaling pathways that
affect oncogenesis, motility, and cell morphology, and
shows increased abundance in the sera of patients with
advanced cancer; PARC (CCL18) also shows increased
abundance in cancer sera, which is consistent with a
previous report on childhood acute lymphoblastic
leukemia (39); and (ii) proteins with moderately differen-
tial expression in early-stage cancer, like gastrokine 2, with
decreased expression in cancer sera, which could be useful
for detection of early-stage cancer since the abundance
changes in half of the early-stage samples in our test,
including one stage-I cancer. Clearly, further test on
larger sample sets is needed.
DISCUSSION
Based on a transcriptomic analysis of 80 pairs of gastric
cancer versus reference tissues, this study has identiﬁed a
number of promising marker genes for gastric cancer in
general, as well as for early-stage cancer. In addition, we
have identiﬁed co-expressed gene clusters and enriched
pathways. This information provides a basis for our
further experimental study aimed to link genes with sub-
stantially altered gene expressions to possible mutations in
the genomes of the cancer patients.
The exon array data collected through this study has
provided wealth of information about splicing variants
in gastric cancer. Based on these results, we have identiﬁed
numerous abnormal splicing variants and abnormally
expressed splicing variants in gastric cancer tissues,
along with their associated pathways, particularly in
early-stage gastric cancer. Our analysis of splicing
variants (see details in Supplementary Procedure 4) and
the analysis results will be reported elsewhere (manuscript
in preparation).
Of the 136 predicted serum marker proteins in our
study, 81 were identiﬁed in the serum samples by different
experimental techniques, and 29 were found to have dif-
ferential abundance in cancer versus control samples,
which is highly encouraging. The discrepancy between
the predicted markers and the validated ones is believed
to be partially due to the fact that we made the serum
marker prediction based on transcriptomic data (in con-
junction with blood secretion prediction), rather than on
proteomic data of cancer and reference tissues, the two of
which are not necessarily always consistent for human
proteins. Another possible reason could be due to the
low abundance of the predicted marker proteins in sera.
In addition, the MS and antibody arrays have detected
proteins showing differential abundance in sera of
cancer patients and the control group that were not pre-
dicted by our computational prediction, which can be
attributed to: (i) some of the detected serum proteins
with differential abundance may not be blood secretory
proteins, instead they might have leaked into circulation;
and (ii) the altered protein abundance in cancer versus
reference tissues may not necessarily be reﬂected by the
transcriptomic data as discussed above.
Nucleic Acids Research,2011, Vol.39, No. 4 1205Clearly, the true effectiveness of the proposed markers
for gastric cancer needs to be validated on larger sample
sets, which we plan to do in the near future at the afﬁliated
hospitals of Jilin University College of Medicine. One way
to improve the efﬁcacy of the proposed serum markers is
to combine individual markers into multi-protein markers
as was done for multi-gene markers. While detailed quan-
titative assessments of multi-protein markers are
challenging due to the lack of accurate quantitative
measures of these proteins in general, we have evaluated
the detection accuracies based on the estimated protein
abundance from the western blots. The preliminary
results given in Supplementary Table S11 show that a k-
protein marker (k 4) could give much improved detec-
tion accuracies than individual serum markers, which
suggests a possible direction for further systematic
analysis.
CONCLUSION
By integrating transcriptomic analyses, computational
prediction and modeling, and proteomic analysis, we
have generated a wealth of information on differentially
expressed genes in gastric cancer versus reference tissues,
their associated biological pathways, marker genes that
can well distinguish cancer tissues from the reference
tissues, and potential serum protein markers for gastric
cancer. Substantial follow-up studies will be conducted
to extend the analysis and clarify in greater detail the
information generated by this study in revealing informa-
tion on carcinogenesis and cancer progression. Limited
clinical tests will be conducted to assess the effectiveness
of the predictive markers based on the 80 pairs of samples
investigated. The novel data generated in this study should
provide highly useful to other researchers, possibly leading
to vastly improved methods for gastric cancer detection
and treatment.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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